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ABSTRACT   28 
Enteric caliciviruses in the genera Norovirus and Sapovirus are important pathogens that 29 
cause severe acute gastroenteritis in both humans and animals. Cyclooxygenases (COXs) 30 
and their final product prostaglandin E2 (PGE2) are known to play important roles in the 31 
modulation of both the host response to the infection and replicative cycle of several 32 
viruses. However, the precise mechanism(s) by which the COXs/PGE2 pathway 33 
regulates sapoviruses replication remains largely unknown. In this study, the infection 34 
of porcine sapovirus (PSaV) Cowden strain, the only cultivable virus within the genus 35 
Sapovirus, markedly increased COX-2 mRNA and protein levels at 24 and 36 hours 36 
post-infection (hpi) with only a transient increase of COX-1 levels seen at 24 hpi. The 37 
treatment of cells with pharmacological inhibitors such as nonsteroidal anti-38 
inflammatory drugs or siRNAs against COX-1 and COX-2 significantly reduced PGE2 39 
production as well as PSaV replication. Expression of the viral proteins VPg and ProPol 40 
was associated with the activation of the COXs/PGE2 pathway. We observed that 41 
pharmacological inhibition of COX-2 dramatically increased NO production, causing a 42 
reduction in PSaV replication that could be restored by inhibition of nitric oxide 43 
synthase via the inhibitor N-nitro-L-Methyl-Arginine-ester. This study has identified 44 
pivotal role for the COXs/PGE2 pathway in the regulation of NO production during the 45 
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sapovirus life cycle, providing new insights into the life cycle of these poorly 46 
characterized family of viruses. Our findings also reveal potential new targets for 47 
treatment of sapovirus infection.  48 
49 
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IMPORTANCE   50 
Sapoviruses are one of major etiological agents of acute gastroenteritis in both humans 51 
and animals, but little is known about sapovirus host factor requirements. Here, using 52 
only cultivable porcine sapovirus (PSaV) Cowden strain, we demonstrate that PSaV 53 
induced the vitalization of cyclooxygenases (COXs) and prostaglandin E2 (PGE2) 54 
pathway. Targeting of COX1/2 using nonsteroidal anti-inflammatory drugs (NSAIDs) 55 
such as the COX-1/2 inhibitor indomethacin and the COX-2 specific inhibitors NS-398 56 
and celecoxib or siRNAs targeting COXs, inhibited PSaV replication. Expression of the 57 
viral proteins VPg and ProPol was associated with the activation of the COXs/PGE2 58 
pathway. We further demonstrate that the production of PGE2 provides a protective 59 
effect against the antiviral effector mechanism of nitric oxide. Our findings uncover a 60 
new mechanism by which PSaV manipulates the host cell to provide an environment 61 
suitable for efficient viral growth, which in turn can be new targets for treatment of 62 
sapovirus infection.   63 
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Diarrhea is the second largest cause of mortality in children worldwide (1). Viruses 64 
within the genera Norovirus and Sapovirus in the family of Caliciviridae are significant 65 
cause of gastroenteritis in humans and animals with noroviruses alone causing ~200,000 66 
deaths per annum in children <5 (2, 3). Despite their socioeconomic impact, the 67 
fastidious nature of viruses within these genera has significantly hindered our 68 
understanding of their life cycle and development of vaccines and therapeutics (4, 5). 69 
Porcine sapovirus (PSaV) is the only cultivable member of the Sapovirus genus and 70 
replicates in the presence of porcine intestinal contents or bile acids (4, 5). Therefore, 71 
PSaV serves as a robust model for studies on the sapovirus life cycle and for the 72 
development of therapeutic interventions (6).  73 
The coexistence of viruses and their hosts imposes an evolutionary pressure on 74 
both the virus and the host immune system. Therefore, viruses have evolved diverse 75 
strategies to create a suitable environment conducive for their existence by either 76 
activating or suppressing cellular pathways to facilitate replication. The 77 
cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) pathway is one of the several host 78 
pathways that participate in the modulation of the host response to the infection and the 79 
replicative life cycle of viruses (7). For example, the activation of COX-2/PGE2 80 
pathway results in increased replication of cytomegalovirus (8, 9), but PGE2 inhibits 81 
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viral replication of parainfluenza 3 virus and adenovirus (10, 11). COXs convert 82 
arachidonic acid released by phospholipases A2- and C-mediated hydrolysis of plasma 83 
membrane phospholipids following exposure to diverse physiological and pathological 84 
stimuli into prostaglandins (PGs), prostacyclines, and thromboxanes (12, 13). Three 85 
forms of COXs have been identified to date with COX-1 and COX-2 being the most 86 
widely studied. COX-1 is constitutively expressed and known to synthesize various PGs 87 
including PGE2 that participate in a diverse range of normal physiological processes 88 
such as cytoprotection of the gastric mucosa, the regulation of renal blood flow, bone 89 
metabolism, nerve growth and development, wound healing, and platelet aggregation 90 
(12, 13). In contrast, COX-2 is rapidly induced by various stimuli including viral 91 
infection, and catalyzes the synthesis of various PGs including PGE2 that have various 92 
activities including pro-angiogenic or anti-apoptotic properties (12, 13). Some of the 93 
biological effects of PGE2 on immunity and inflammation are exerted through the 94 
binding to G-protein coupled receptors on the plasma membrane called E prostanoid 95 
receptors (14). PGE2 is recognized as the major prostanoid produced in immune and 96 
nonimmune cells, and acts as potent regulators of cell-cell interaction, antigen 97 
presentation, cytokine production, differentiation, survival, apoptosis, and cell migration 98 
(14). 99 
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This study sets to examine the potential role of COXs/PGE2 pathway in the 100 
regulation of the sapovirus life cycle. We demonstrate that COXs/PGE2 pathway is 101 
induced during PSaV replication and that this induction occurs following the expression 102 
of the viral VPg and protease-polymerase (ProPol) proteins. We further demonstrate 103 
that the production of PGE2 provides a protective effect against the antiviral effector 104 
mechanism of nitric oxide (NO), uncovering a new mechanism by which 105 
enteropathogenic viruses manipulate the host cell to provide an environment suitable for 106 
efficient viral growth.  107 
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MATERIALS AND METHODS 108 
Cell and virus. LLC-PK porcine kidney cells obtained from the American Type Culture 109 
Collection (ATCC, USA) were maintained in Eagle’s minimal essential medium 110 
(EMEM) containing 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 μg/ml 111 
streptomycin. The tissue culture-adapted PSaV Cowden strain was recovered from the 112 
full-length infectious clone pCV4A, and was propagated in LLC-PK cells with the 113 
supplement of bile acid (15). 114 
 115 
Chemicals and antibodies. Celecoxib, NS-398, SC-58125, SC-236, 116 
nimesulide and SC-560 were purchased from Cayman Chemical (Ann Arbor, MI, USA). 117 
Glycochenodeoxycholic acid (GCDCA), dimethyl sulfoxide (DMSO), L-NAME, MDL-118 
12330A and indomethacin were from Sigma-Aldrich (St. Louis, MO, USA). COX-1 119 
siRNA, COX-2 siRNA and scrambled siRNA were purchased from Santa Cruz 120 
Biotechnology, Inc., (CA, USA). Monoclonal antibody (Mab) against mouse COX-1 121 
and polyclonal antibody against rabbit COX-2 were obtained from Abcam (Cambridge, 122 
MA, UK). Mouse Mab against hemagglutinin (HA) tag was purchased from OriGene 123 
(Rockville, MD, USA). Synthetic PGE2 was purchased from Tocris Bioscience 124 
(Ellisville, MO, USA). The anti-PSaV capsid Mab and the anti-PSaV VPg polyclonal 125 
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antibody were previously described (16). Secondary antibodies used were horse radish 126 
peroxidase conjugated goat immunoglobulin against rabbit IgG (Cell Signaling, Beverly, 127 
MA., USA) and mouse IgG (Santa Cruz), and fluorescein isothiocyanate (FITC) 128 
conjugated goat immunoglobulin against rabbit IgG (Jackson Immuno Research Lab, 129 
PA., USA). 130 
 131 
Cytotoxicity assay. The cytotoxicity of the chemicals used in this study was 132 
determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 133 
(MTT) assay (17, 18) as per the manufacturer’s instructions. Briefly, cells in 96 well 134 
plates were incubated with medium containing different concentration of various 135 
chemicals for 24 hr. After removal of the media, 200 μl of MTT solution was added to 136 
each well and incubated for 4 hr at 37℃ in a CO2 incubator. Each well was added with 137 
150 μl of DMSO and incubated at room temperature for 10 min. The absorbance was 138 
read in an ELISA reader at 570 nm. The percentage of cell viability was calculated 139 
using the following formula: [OD(sample) – OD(blank) / (OD(control) – OD(blank)] x 100. Non-140 
toxic concentrations of each chemical were used in this study. 141 
 142 
Treatment of inhibitors and chemicals into LLC-PK cells. LLC-PK cells 143 
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were grown in 6 or 12 well plates to attain the desired confluency. The chemicals and 144 
inhibitors were dissolved in DMSO to make a 10 mM stock concentration. When 145 
appropriate, a series of dilutions were made by diluting the appropriate volumes of 146 
chemical or inhibitor stocks in EMEM. Treatment groups were typically as follows: 147 
mock-treatment, pre-treatment, post-treatment, and pre-post-treatment. Confluent LLC-148 
PK cells were pre-treated with various concentrations of the inhibitors for 24 h. The 149 
cells were washed with phosphate-buffered saline (PBS, pH 7.4) and inoculated with 150 
PSaV at a multiplicity of infection (MOI) of 1 fluorescent focus unit (ffu)/cell. For post-151 
treatment groups, different concentrations of inhibitors were added in the maintenance 152 
media after the virus adsorption step. For the pre-post treatment groups, LLC-PK cells 153 
were pre-treated with different concentrations of inhibitors for 24 h. After removal of 154 
inhibitors, the cells were washed twice with PBS and inoculated with PSaV. The 155 
inhibitors were again added at the end of virus adsorption period. 156 
 157 
Plasmid constructs and cell culture. Each of the regions coding for the PSaV 158 
proteins, NS1, NS2, NS3, NS4, NS5, NS6-7, VP1, and VP2 (19) was amplified from the 159 
full-length infectious clone pCV4A by PCR assays with primer pairs containing SalI 160 
and NheI restriction enzyme sites (Table 1). Each forward primer specific for above 161 
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gene(s) had N-terminal HA tag sequences (Table 1). Each amplicon was purified by 162 
PuriGel (Invitrogen, Waltham, MA, USA) following the manufacturer’s instruction and 163 
subcloned into pUNO cloning vector (InvivoGen, San Diego, CA, USA). All amplified 164 
regions were verified by Sanger sequencing. Plasmid constructs inserted with different 165 
viral genes or empty vector were individually transfected in LLC-PK cells grown in 6 166 
well plates using the Lipofectamine® 2000 reagent (Invitrogen) following the 167 
manufacturer’s instruction. Cell were harvested at different post-transfection points, and 168 
subjected to quantitative real-time PCR and Western blot analysis using the anti-HA 169 
antibody. 170 
 171 
In vitro transcription and RNA transfection. LLC-PK cells were seeded in 6-172 
well or 24-well plates and transfected with 1 μg of capped in vitro transcribed PSaV 173 
RNA using Lipofectamine 2000® (Invitrogen). The capped in vitro transcripts were 174 
derived from the full-length PSaV cDNA clone pCV4A (20) by the mMESSAGE 175 
mMACHINE Kit (Ambion, Austin, TX, USA) following the manufacturer’s instruction. 176 
Transfections were performed for 4 h and media was replenished with eagle’s minimum 177 
essential medium (EMEM) supplemented with or without 200 µM GCDCA. After 6 178 
days post transfections, cells were lysed, harvested and subjected to immunoblotting 179 
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and qPCR to analyze COX-1, COX-2 and PSaV VPg levels.  180 
 181 
siRNA transfection. LLC-PK cells were cultured in 6 or 12 well culture plates 182 
at 70-80% confluency and transfected with siRNA (80 pmole of COX-1, COX-2, and 183 
scrambled control siRNA) using the Lipofectamine® 2000 reagent (Invitrogen) 184 
following the manufacturer’s instruction. Cells were then infected with PSaV at a MOI 185 
of 1 ffu/cell. After 1 h, unabsorbed viruses were removed and the cells were maintained 186 
in EMEM with 2.5% FBS and 100 μM GCDCA. Cells were harvested at different time 187 
points and subjected to qPCR, median tissue culture infective dose (TCID50) and 188 
Western blot analyses. 189 
 190 
Preparation of cell extract and Western blot analysis. Confluent LLC-PK 191 
cells in 6 well plates infected with or without PSaV, treated with or without chemicals or 192 
inhibitors, transfected with or without siRNAs, or transfected with or without each gene 193 
construct of PSaV were harvested at different time points. The cells were washed twice 194 
with PBS and lysed with a cell extraction buffer (Invitrogen) supplemented with 195 
protease and phosphatase inhibitors (Roche, Basel, Switzerland). Total cell lysates were 196 
denatured and resolved in sodium dodecyl sulfate (SDS)-polyacrylamide gels. The 197 
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resolved proteins were transferred in nitrocellulose blotting membrane (Amersham 198 
Protran, GE Healthcare Life science, Germany) and immunoblotted with primary 199 
antibodies specific to COX-1, COX-2, glyceraldehyde 3-phosphate dehydrogenase 200 
(GAPDH), HA or PSaV VPg. Secondary antibodies against rabbit or mouse IgG were 201 
applied after the primary antibody. Immunoreactive bands were developed using the 202 
enhanced chemoluminescence reaction kit (DoGen, Seoul, South Korea) and images 203 
were taken using the Davinch-Western Imaging System (Young Ltd., Kang-nam, Seoul, 204 
South Korea). To confirm equal protein loading, transferred blotting membranes were 205 
also incubated with an antibody against GAPDH and its reactivity was compared with 206 
the intensity of target bands. The quantification of the protein density for COX-1 and 207 
COX-2 were performed using Image Studio Lite (LI-COR Biotechnology, Lincoln, NE, 208 
USA) and was normalized to the corresponding density of GAPDH of the same samples. 209 
 210 
RNA isolation. For quantifying intracellular RNA levels of signaling molecules, 211 
mock- or PSaV-infected, chemical or inhibitor treated, or siRNA transfected cells were 212 
washed twice with PBS, scraped and collected in clean microtubes. Samples were 213 
centrifuged at 10,000 rpm for 10 mins and total RNA was isolated using the PureLink 214 
RNA mini kit (Ambion Life technologies, Carlsbad, CA., USA) following the 215 
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manufacturer’s instructions. For quantifying PSaV RNA, mock- or PSaV-infected, 216 
chemical or inhibitor treated, or siRNA transfected cells were freeze-thawed three times, 217 
and cell debris was spun down at 2,469 x g for 10 min at 4 ˚C. The supernatants along 218 
with the remaining bulk samples were collected and stored at −80˚C until used. Total 219 
RNA was extracted from supernatants using RNeasy kit (Qiagen) following the 220 
manufacturer’s instructions. The RNA concentrations were spectrophotometrically 221 
determined at 260 nm using the BioPhotometer plus (Eppendorf, Hamburg, Germany). 222 
 223 
Quantitative real-time PCR. cDNAs were prepared by using 1 μg of RNA and 224 
reverse transcribed using random hexamers (Promega, Madison, WI., USA). The 225 
oligonucleotide primers used in the quantitative real-time PCR were designed from the 226 
published sequences of COX-1, COX-2, and PSaV VPg (Table 1). Reactions were set 227 
up in 25 μl volumes containing 10 pmol of forward and reverse primers, cDNA, and 228 
TOPreal qPCR 2X PreMIX (Enzynomics, Daejon, South Korea). For COX-1 and COX-229 
2, the amplification profile was as follows: 1 cycle of initial denaturation at 95ºC for 10 230 
min, 45 cycles of denaturation at 95ºC for 10 s, primer annealing at 55ºC for 30 s and 231 
extension at 72ºC for 45 s. The amplification profile for VPg included 1 denaturation at 232 
95ºC for 10 min, followed by 40 cycles of denaturation 95ºC for 10 s, primer annealing 233 
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at 60ºC for 20 s and extension at 72ºC for 20 s. Relative expressions of COX-1 and 234 
COX-2 levels were calculated by the using 2-ΔΔ CT (21). Samples were normalized to 235 
the quantity of β-actin gene. The copy number of the VPg gene was calculated using 10-236 
fold dilutions of known amount of pCV4A to generate the standard curve. 237 
 238 
TCID50 assay. The TCID50 assay was performed as previously described (6). 239 
Briefly, ten-fold serial dilutions of clarified virus supernatants were prepared in EMEM. 240 
Of these dilutions, 200 µl was inoculated to monolayers of LLC-PK cells grown on 96-241 
well plates supplemented with 200 µM GCDCA and incubated at 37oC in a 5% CO2 242 
incubator. Virus titers were calculated at 6 days post-infection and expressed as 243 
TCID50/ml values by the method of Reed and Muench (22). 244 
 245 
Determination of the infectivity titer by immunofluorescence assay. 246 
Infectivity assay was carried out as described previously (16). Briefly, confluent 247 
monolayers of cells on the confocal dish were treated with various inhibitors or 248 
chemicals as described above. Mock or treated cells were infected with PSaV at a MOI 249 
of 1 ffu/cell and incubated at 37℃ for 1 hr. Cells were washed three times with PBS, 250 
replaced with maintenance medium and then incubated for 36 hr at 37℃ prior to being 251 
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fixed with 4% formaldehyde in PBS.  252 
Immunofluorescence assay was performed as previously reported (16). Briefly, 253 
fixed cells in 8-well chamber slides were permeabilized by the addition of 0.2% Triton 254 
X-100, incubated at room temperature for 10 min, and washed with PBS containing 0.1% 255 
newborn calf serum (PBS-NCS). Chamber slides were added with anti-PSV capsid 256 
(1:40 dilution) Mab and then incubated at 4℃ overnight. Cells were then washed three 257 
times with PBS-NCS. FITC-conjugated goat secondary antibody (diluted to 1:100) was 258 
then added. After washing with PBS, chambers were mounted with SlowFade Gold 259 
antifade reagent (Life technologies, Eugene, OR, USA) containing DAPI solution for 260 
nucleus staining. Infected cells were observed with a LSM 510 confocal microscope and 261 
analysed using LSM software (Carl Zeiss). To calculate the percentage of antigen-262 
positive cells in each well, 1,000 cells in each well were counted, using a 40x objective 263 
and a 10x eyepiece, yielding a final magnification of 400x. The percentage of antigen-264 
positive cells between mock- and drug-treated or scrambled RNA- and siRNA against 265 
COX-2 gene was compared. 266 
 267 
Determination of NO concentration. The concentration of NO was determined in 268 
culture supernatant of mock- or PSaV-infected cells in the presence or absence of 269 
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chemicals or inhibitors by assaying nitrite, one of its stable end products. Collected 270 
supernatants were centrifuged to remove cell debris. The assay was done using the 271 
Griess reagent system (Promega, Madison, WI., USA) according to the manufacturer’s 272 
instruction. Briefly, equal volume of each experimental sample and sulfanilamide 273 
solution were incubated at room temperature for 10 min. An equal volume of N-1-274 
naphthylethylenediamine dihydrochloride solution was then added to all wells and 275 
incubated for 10 min. The absorbance was read at 540 nm in a plate reader. The nitrite 276 
concentration for each sample was determined by comparing it with a generated nitrite 277 
standard and calculated by linear regression analysis.  278 
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RESULTS 279 
PSaV infection induces COXs expression and leads to the production of PGE2. To 280 
determine whether the COXs/PGE2 pathway was activated during PSaV replication, we 281 
examined the impact of PSaV replication on COX gene expression. COX-2 mRNA and 282 
protein levels were markedly piled up at 24 and 36 hours post-infection (hpi) 283 
concomitant with the increase in PSaV viral RNA and protein levels, whereas COX-1 284 
levels were transiently increased at 24 hpi only (Fig. 1A–C). The level of PGE2 in the 285 
infected cell culture supernatant was also significantly elevated from 12 hpi (Fig. 1D).  286 
To confirm whether the observed increase in soluble PGE2 was as a direct result of 287 
the PSaV-mediated induction of COX-1 and COX-2, the effect of selective or non-288 
selective COX inhibitors on PGE2 production was examined (Fig. 2). Importantly, all 289 
studies were performed at doses of inhibitors shown not to affect cell viability under the 290 
experimental conditions used (data not shown). The non-selective COX-1/2 inhibitor 291 
indomethacin and the selective COX-2 inhibitor NS-398 both inhibited PSaV-mediated 292 
PGE2 production in a dose-dependent manner when added either immediately after the 293 
removal of the virus inoculum (Post treatment) or during the entire course of the 294 
infection (Pre-Post treatment) (Fig. 2A and B). In contrast, due to the reversible nature 295 
of the inhibitors, the pretreatment of cells and subsequent removal of the inhibitor prior 296 
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to the addition of PSaV had no effect on the levels of PGE2 production (Fig. 2A and B). 297 
Similar results were also obtained with a range of other COX inhibitors (Fig. 2C and D; 298 
data not shown). 299 
To further confirm a direct role for COX-1 and COX-2 in the production of PGE2 300 
during PSaV infection, the effect of COX-1 or COX-2 specific siRNAs was also 301 
examined. Transfection of siRNA against COX-1 or COX-2 into LLC-PK cells reduced 302 
expression levels of their respective target proteins. Although the inhibition of both 303 
intracellular proteins was not complete by siRNA transfection, the levels of PGE2 304 
released from COX-1 and COX-2 siRNA-transfected cells were significantly reduced 305 
(Fig. 2E and F). These results confirmed that the inductions of both COX enzymes are 306 
responsible for the observed increase in PGE2 from PSaV-infected cells. In addition, the 307 
level of siRNA-mediated reduction of COX-1 and COX-2 was sufficient to significantly 308 
reduce the production of PGE2. 309 
 310 
Inhibition of both COX enzymes negatively regulates PSaV replication. To 311 
determine the impact of COX induction on PSaV replication, we examined the effect of 312 
COX inhibitors and siRNAs on PSaV replication. Cells were treated with either 313 
inhibitors (selective or nonselective) or transfected with siRNAs specific for COX-1 or 314 
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COX-2, and the effect on virus replication was monitored at 36 hpi by examining viral 315 
titers as well as viral RNA and protein levels. There was no significant effect of COX 316 
inhibitors on PSaV replication when cells were pre-treated but the inhibitors were 317 
removed prior to infection (Pre) (Fig. 3A-H; Fig. 4A-D). However, the inclusion of 318 
COX inhibitors following the removal of the virus inoculum (Post) or during the entire 319 
course of infection (Pre-Post) resulted in a significant reduction in PSaV replication (Fig. 320 
3A-H, Fig. 4A-D). The COX-1 inhibitor SC-560 reduced the levels of PSaV RNA and 321 
infectious virus by up to ~10 fold at 36 hpi (Fig. 3G-H). In contrast, COX-2 specific 322 
inhibitors NS-398 and celecoxib, and non-selective COX-1/2 inhibitor indomethacin 323 
showed a more significant effect, typically leading to a ~1000 fold decrease in virus 324 
yield and RNA synthesis (Fig. 3A-F). Other specific COX-2 inhibitors (SC-58125, SC-325 
236, and nimesulide) were also tested; however less robust inhibition against PSaV 326 
replication was observed (data not shown).  327 
The effect of COX-specific siRNAs on PSaV replication was also examined (Fig. 328 
3I-L; Fig. 4E and F). Transfection of COX-2 specific siRNA had a more substantial 329 
effect on PSaV replication than COX-1 siRNAs, causing an ~1000 fold reduction in 330 
viral titer with a concomitant decrease in viral RNA levels and viral protein production 331 
(Fig. 4E and F). Infection assays also demonstrated that treatment of cells with either 332 
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NS-398 or transfection with COX-2 specific siRNAs resulted in a significant decrease 333 
in the number PSaV antigen-positive cells (Fig. 4G). Combined these data suggest that 334 
both COX-1 and COX-2 enhance PSaV replication possibly via the increased 335 
production of PGE2. 336 
 337 
Supplementation of PGE2 relieves the COX inhibition of PSaV replication. 338 
If the pro-viral effect of COX gene induction on PSaV replication was due solely to the 339 
production of increased PGE2, then the addition of PGE2 would be expected to reverse 340 
the inhibitory effect of COX inhibitors on virus replication. To examine this possibility, 341 
the ability of exogenous PGE2 to restore PSaV replication after treatment with the non-342 
selective COX-1/2 inhibitor indomethacin and the COX-2 specific inhibitor NS-398 343 
was examined. The addition of exogenous PGE2 led to a dose-dependent restoration of 344 
both PSaV infectivity and viral RNA levels in cells treated with either inhibitor (Fig. 5). 345 
These results confirmed that PGE2, the final product of both COX enzymes, mediates 346 
the pro-viral effects of COX gene induction on PSaV replication. 347 
 348 
Bile acid does not influence COX-2 expression during PSaV infection. 349 
PSaV replication in cell culture relies on the presence of bile acids including GCDCA in 350 
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the cell culture medium through a function that had previously been linked to an effect 351 
of bile acids on the innate immune response to infection (15). However, recent studies 352 
have indicated that this initial conclusion was incorrect as PSaV remains sensitive to the 353 
type I interferon (IFN) response in the presence of bile acids (6) and that bile acids 354 
function to promote virus uncoating (23). To determine whether bile acids have an 355 
effect on the induction of COX-2/PGE2 pathway during PSaV replication, the induction 356 
of COX-2 and PGE2 was examined in the presence or absence of GCDCA following the 357 
transfection of in vitro transcribed and capped PSaV genome (Fig. 6). Transfected RNA 358 
was used to bypass any role of GCDCA which may play during viral entry and 359 
uncoating (23). We observed that COX-2 and PGE2 were induced in cells transfected 360 
with in vitro transcribed and capped PSaV genomic RNA, irrespective of whether 361 
GCDCA was present or absent (Fig. 6A). As expected, the COX-2 inhibitor NS-398 362 
reduced expression of COX-2 and PGE2, and replication of PSaV (Fig. 6A-D). These 363 
data indicate that induction of COX-2 and PGE2 was a direct result of PSaV replication 364 
and was not due to any supplementary effect of GCDCA.  365 
 366 
PSaV VPg and ProPol activate COX-2/PGE2 pathway. Given our 367 
observation that PSaV replication was required for the induction of the COX-2/PGE2 368 
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pathway, we investigated whether the expression of viral protein alone was sufficient. 369 
The LLC-PK cells were transfected with plasmid carrying each PSaV gene including 370 
NS1, NS2, NS3, NS4, NS5, NS6-7, VP1, and VP2 (19). Expression of each viral protein 371 
was confirmed via the detection of a HA tag fused to the N-terminus of each protein 372 
(Fig. 7A). Western blotting and qPCR analysis of the levels of COX-1 and COX-2 373 
demonstrated that VPg or ProPol expression significantly enhanced the expression of 374 
COX-2 and led to an increase in PGE2 production (Fig. 7B-D).  375 
 376 
PGE2 blocks the antiviral effect of nitric oxide (NO). Previous studies have 377 
indicated that at least one of the effects of the prostaglandin production is the regulation 378 
of nitric oxide (NO) production (24). NO is a key molecule involved in the host defense 379 
mechanism against various pathogens including protozoans, parasites, fungi, bacteria, 380 
and viruses (25). NO also has a regulatory role at many stages of the development of 381 
inflammation (26). To determine if the PGE2 produced during PSaV replication 382 
impacted NO production, we first examined the level of NO produced during PSaV 383 
replication. PSaV infected cells maintained low level of NO prior to 36 hpi when upon a 384 
significant increase in PGE2 production was observed (Fig. 8A). These data suggested 385 
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that COX induction and the associated increase in PGE2 production may play an 386 
important role in the inhibition of NO production during PSaV replication.  387 
To examine this possibility further, the effect of the COX-2 inhibitor NS-398 on 388 
NO production during PSaV infection was also examined (Fig. 8B). Inhibition of COX-389 
2 activity was found to lead to a concomitant increase in NO production during PSaV 390 
replication, which could be reversed in a dose-dependent manner by the addition of 391 
nitric oxide synthase (NOS) inhibitor, L-NAME (Fig. 8B). The reversal of the effect of 392 
COX-2 inhibition by L-NAME also resulted in a subsequent restoration of PSaV 393 
infectivity levels as well as PSaV RNA and protein levels (Fig. 8C-E). Collectively, 394 
these data suggest that the pro-viral effects of PGE2 produced by both COX-1 and 395 
COX-2 enzymes as a result of PSaV infection are mediated by the inhibition of the 396 
antiviral effect of the NO.   397 
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DISCUSSION 398 
During viral infection, numerous host inflammatory responses are induced, leading to 399 
the production of cellular effectors and soluble factors such as IFNs, PGE2 and NO (27, 400 
28). As obligate intracellular parasites, viruses must therefore subvert and/or avoid the 401 
host response to infection in order to complete their life cycle. As a result, pathogens 402 
including viruses have evolved a wide variety of mechanisms that enable the control of 403 
cellular pathways, evade the host immune response and hijack signaling pathways to 404 
facilitate viral replication and pathogenesis. Here, we investigated the potential role of 405 
the COXs/PGE2 pathway in the PSaV life cycle and the control of infection. We found 406 
that the COXs/PGE2 pathway was activated during the PSaV life cycle and that this 407 
activation had pro-viral effects via the inhibition of NO production. Furthermore, we 408 
determined that expression of the VPg and ProPol proteins of PSaV was sufficient to 409 
induce COX expression and PGE2 production. 410 
Among the soluble factors produced during the response of host cells to viral 411 
infection, NO is well known in the antiviral repertoire (29-32). In the immunological 412 
system, iNOS is induced by cytokines at the transcriptional level primarily in 413 
macrophages, neutrophils, epithelial cells, and hepatocytes where NO is produced in 414 
high concentrations (33, 34). Inducible NOS (iNOS), the enzyme responsible for the 415 
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production of NO, can be regulated by the COX/PGE2 pathway (31). NO production is 416 
known to restrict the VSV infection (29), an effect that is similarly thought to be offset 417 
by the induction of PGE2 production during VSV replication in vivo (24). Here, we 418 
showed that activation of the COX-2/PGE2 pathway also enhances PSaV replication 419 
through an inhibitory effect on NO production. 420 
NO production is significantly enhanced in patients suffering from gastroenteritis 421 
(30); this has been observed in norovirus or rotavirus infections in children (32). NO 422 
secretion can be triggered in vitro and in vivo by the rotavirus nonstructural protein 4 423 
(NSP4) (34-36) which in turn may cause diarrhea by elevating intestinal permeability 424 
(37, 38), regulating intestinal motility (39) and intestinal ion transport (40, 41). In 425 
contrast to rotavirus infection (34-36), little NO production was observed during PSaV 426 
replication in the LLC-PK cells, possibly due to the synthesis of PGE2, suggesting that 427 
NO may not be involved in sapovirus-induced diarrhea. However, it is important to note 428 
that we cannot fully rule out the potential role for NO in PSaV pathogenesis in vivo, 429 
where the cellular response to infection is influence by numerous cell types and may not 430 
be entirely reproduced in immortalized cells in vitro.  431 
In a few instances, viral proteins have been identified to stimulate the activation of 432 
COXs/PGE2 pathway, often by acting either directly or indirectly as a transcriptional 433 
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transactivator of COX-2 gene expression (42-45). Among the viral proteins for which 434 
this activity has been reported, the hepatitis C virus (HCV) protein NS3, a viral serine 435 
protease, is known to enhance COX-2/PGE2 pathway by activating multiple signaling 436 
pathways (46). In addition, the severe acute respiratory syndrome coronavirus (SARS-437 
CoV) nucleocapsid protein also activates the expression of COX-2/PGE2 pathway by 438 
binding directly to regulatory elements for NF-κB and CCAAT/enhancer binding 439 
protein (45). In the present study, we demonstrated that expression of the PSaV VPg or 440 
ProPol proteins in isolation was sufficient to lead to the activation of COX-2/ PGE2 441 
pathway. The mechanism behind this activation remains to be determined and is the 442 
subject of future study.  443 
In the present study, the levels of COX-1/2 mRNA and proteins were increased in 444 
the response to PSaV infection so that we evaluated the effect of COX-1 specific, COX-445 
2 specific or non-selective COX-1/2 inhibitors on PSaV replication. Among these 446 
inhibitors tested, COX-2 specific inhibitors NS-398 and celecoxib, and non-selective 447 
COX-1/2 inhibitor indomethacin exerted stronger anti-PSaV effects than other inhibitors; 448 
having a ~1000 fold decrease effect in virus yield and RNA synthesis. However, other 449 
specific COX-2 inhibitors had less strong inhibitory effect against PSaV replication, 450 
most likely due to their less potent activity and the fact that higher concentrations 451 
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required for effective COX inhibition resulted in cell toxicity observed during their use. 452 
In addition, a more robust inhibitory effect of COX-2 specific inhibitor NS-398 and the 453 
COX-1/2 nonselective inhibitor indomethacin on PSaV replication was observed in 454 
post-treatment compared with the pre-post-treatment. The mechanism why post-455 
treatment of these inhibitors has stronger effect than pre-post-treatment remains 456 
unknown. The one possibility is that it could be an off-target effect of using high dose of 457 
these inhibitors in the LLC-PK cells, although there are no published reports of these 458 
kinds of phenomena.  459 
In the present study, we observed only a transient increase in COX-1 levels during 460 
PSaV infection whereas COX-2 induction was more significantly induced and induction 461 
was sustained during the later stage of the viral life cycle. However, the dramatic effect 462 
of the non-selective COX inhibitor indomethacin, the COX-2 specific inhibitor NS-398 463 
and the effect of COX-specific siRNAs support the hypothesis that both COX-1 and 464 
COX-2 enzymes play a role to the PSaV replication.  465 
In conclusion, our results demonstrate crucial role for the COXs/PGE2 pathway in 466 
the regulation of NO production during the PSaV replication, which provide an 467 
environment suitable for efficient PSaV growth. In addition, our data would indicate 468 
that pharmacological targeting of COX-2 could provide a potential targeting strategy for 469 
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the control of sapovirus infection facilitating the antiviral effect of NO production. 470 
Further studies are required to determine if targeting of the COXs/PGE2 pathway in vivo 471 
has a negative impact on PSaV pathogenesis.  472 
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FIGURE LEGENDS  635 
FIG 1 Induction of COX-1 and COX-2 by PSaV infection. (A and B) The expression of 636 
COX-1, COX-2, and PSaV viral RNA in LLC-PK cells infected with PSaV (MOI = 1 637 
ffu/cell) was quantified by real-time PCR (qPCR). In the case of COX-1 and COX-2, 638 
expression levels were normalized to β-actin and are depicted as the fold induction 639 
compared with that of the mock inoculated cells. (C) The levels of the VPg, COX-1, 640 
COX-2 and GAPDH proteins were analyzed by Western blot. GAPDH was used as a 641 
loading control. (D) The levels of PGE2 in the supernatants harvested at 36 hours post-642 
infection (hpi) from PSaV-infected LLC-PK cells were determined by ELISA. The 643 
levels of PGE2 in the supernatants were compared between mock- and virus-inoculated 644 
groups. Data are presented as means ± standard error of the mean from three 645 
independent experiments. Differences were evaluated using the One-Way ANOVA. 646 
**p<0.001; ***p<0.0001. 647 
 648 
FIG 2 Effects of COX-2 inhibitors in PGE2 production during PSaV infection (A-D) 649 
LLC-PK cells were treated with selective COX-2 inhibitors (NS398 and celecoxib), 650 
nonselective COX inhibitor (indomethacin), and selective COX-1 inhibitor (SC-560) as 651 
indicated prior to the addition of the virus inoculum (MOI = 1 ffu/cell) and then 652 
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removed (Pre), after the addition of the virus inoculum then left for the duration of the 653 
infection (Post) or treated prior to the addition of the inoculum as well as for the 654 
duration of the infection (Pre-Post). The levels of PGE2 in the supernatants harvested at 655 
36 hpi were determined by ELISA. The levels of PGE2 in the supernatants of virus-656 
infected cultures were compared between mock- and chemical-treated groups. (E-F) 657 
Confluent of LLC-PK cells was transfected with siRNAs against COX-1, COX-2 or 658 
scrambled-siRNA (Scram-siRNA) prior to infection with PSaV (MOI = 1 ffu/cell). 659 
Supernatants were collected and ELISA was conducted to determine the PGE2 660 
concentration. The levels of PGE2 in the supernatants were compared between mock- 661 
and siRNA-transfected groups. (Inset) Western blot analysis for COX-1, COX-2 and 662 
GAPDH was conducted with LLC-PK cells transfected with COX-1, COX-2 or 663 
scrambled-siRNA (Scram-siRNA). Data are presented as means ± standard error of the 664 
mean from three independent experiments. Differences were evaluated using the One-665 
Way ANOVA. **p<0.001; ***p<0.0001. 666 
 667 
FIG 3 Inhibition of COXs attenuates PSaV replication. (A-F) LLC-PK cells were pre-668 
treated (Pre), post-treated (Post) or pre-post-treated (Pre-Post) with non-cytotoxic doses 669 
of NS-398, indomethacin, celecoxib, and SC560. At 36 hours post-inoculation (hpi) 670 
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with PSaV (MOI = 1 ffu/cell), cells were harvested and the levels of viral RNA (A, C, E, 671 
and G) and titer (B, D, F, and H) were determined by quantitative real-time PCR and 672 
TCID50, respectively. (I-L) LLC-PK cells were transfected with siRNAs against COX-1, 673 
COX-2 or scrambled-siRNA (Scram-siRNA) before inoculation with PSaV (MOI = 1 674 
ffu/cell). Samples were harvested at 36 hours post-inoculation (hpi) and the levels of 675 
viral RNA (I and K) and titer (J and L) were determined by quantitative real-time PCR 676 
and TCID50, respectively. Data are displayed as the mean ± standard error of the mean 677 
from three independent experiments. Differences were evaluated using the One-Way 678 
ANOVA. *p<0.05, **p<0.001, ***p<0.0001. 679 
 680 
FIG 4 Effect of COX inhibitors or siRNA in PSaV replication. (A-D) LLC-PK cells 681 
were pre-treated (Pre), post-treated (Post) or pre-post-treated (Pre-Post) with non-682 
cytotoxic doses of NS-398, indomethacin, celecoxib, and SC560. At 36 hours post-683 
inoculation (hpi) with PSaV (MOI = 1 ffu/cell), cells were harvested and the level of 684 
protein of viral VPg was determined by Western blot analyses. (E-F) LLC-PK cells were 685 
transfected with siRNAs against COX-1, COX-2 or scrambled-siRNA (Scram-siRNA) 686 
before inoculation with PSaV (MOI = 1 ffu/cell). Samples were harvested and 687 
processed as mentioned above. GAPDH was used as a loading control. (G) LLC-PK 688 
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cells were infected with PSaV (MOI = 1 ffu/cell) and the effect of the COX-2 inhibitor 689 
NS-398 on viral antigen production was determined by confocal microscopy. 690 
 691 
FIG 5 Addition of exogenous PGE2 reverses the effect of COX inhibitors on PSaV 692 
replication. LLC-PK cells were infected with PSaV (MOI = 1 ffu/cell), treated with 693 
non-cytotoxic doses of NS-398 or indomethacin and then supplemented with exogenous 694 
PGE2 in the maintenance media. After 36 hours post-infection, cells were harvested and 695 
the levels of viral RNA synthesis (A and C) and titer (B and D) were determined by 696 
quantitative real-time PCR and TCID50, respectively. Data are represented as the means 697 
± standard error of the mean from three independent experiments. Differences were 698 
evaluated using the One-Way ANOVA. *p<0.05; **p<0.001; ***p<0.001. 699 
 700 
FIG 6 Bile acid GCDCA does not influence the expression of COX-2 during PSaV 701 
infection. LLC-PK cells were either infected with PSaV (MOI = 1 ffu/cell) or 702 
transfected with one microgram of in vitro transcribed PSaV capped RNA, and the 703 
effect of the COX-2 inhibitor NS-398 or the bile acid GCDCA were examined. Infected 704 
cells were harvested at 36 hours post-infection whereas transfected cells were harvested 705 
after 6 days post-transfection and subjected to Western blot analysis to assess viral 706 
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protein production (A), as well as to qPCR for viral RNA (B) and COX-2 (C). 707 
Supernatants were also collected for ELISA to quantify the levels of PGE2 (D). Data are 708 
represented as the means ± standard error of the mean from three independent 709 
experiments. Differences were evaluated using the One-Way ANOVA. **p<0.001; 710 
***p<0.001. 711 
 712 
FIG 7 Role of PSaV proteins in stimulating COX-2 expression. LLC-PK cells were 713 
transfected with one microgram of pUNO plasmids containing each PSaV gene tagged 714 
with a HA epitope as indicated in the materials and methods section. As controls, pUNO 715 
empty or HA carrying (pUNO-HA) plasmids were transfected. At 36 hours post-716 
transfection (hpt), cells were harvested and the expression levels of viral proteins (A) as 717 
well as COX-1 and COX-2 (B) proteins were determined by Western blot analysis. 718 
GAPDH was used as a loading control. In the case of COX-1 and COX-2, the 719 
expression levels were also quantified by real-time PCR, normalized to β-actin and 720 
depicted as the fold induction compared with that of the vehicle transfected cells (C). To 721 
determine the PGE2 concentration, supernatants were collected and ELISA was 722 
conducted (D). The levels of PGE2 in the supernatants were compared between vehicle- 723 
and PSaV gene-transfected groups. Data are presented as means ± standard error of the 724 
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mean from three independent experiments. Differences were evaluated using the One-725 
Way ANOVA. ** p<0.001, ***p<0.0001.  726 
 727 
FIG 8 PGE2 blocks the antiviral effect of nitric oxide (NO) for PSaV infection. (A) 728 
Supernatants from mock- or PSaV-infected samples were collected and the nitrite 729 
concentration was determined using the Griess reagent system as described in the 730 
materials and methods section. LLC-PK cells were infected with PSaV (MOI = 1 731 
ffu/cell) and subsequently treated with the COX-2 inhibitor NS-398 or the nitric oxide 732 
synthase inhibitor L-NAME, either singularly or in combination. (B) The effect of 733 
inhibitor treatment on nitric oxide production was then determined as described for 734 
panel (A). The levels of viral titer (C), RNA (D), and protein (E) were determined by 735 
TCID50, real-time RT-PCR, and Western blot analyses, respectively. GAPDH served as 736 
the loading control. Data are means ± standard error of the mean from three different 737 
independent experiments. Differences were evaluated by One-Way Anova. ***p<0.0001. 738 
 o
n
 February 9, 2017 by M
EDICAL RESEARCH CO
UNCL - UK SBS
http://jvi.asm.org/
D
ow
nloaded from
 
 o
n
 February 9, 2017 by M
EDICAL RESEARCH CO
UNCL - UK SBS
http://jvi.asm.org/
D
ow
nloaded from
 
 o
n
 February 9, 2017 by M
EDICAL RESEARCH CO
UNCL - UK SBS
http://jvi.asm.org/
D
ow
nloaded from
 
 o
n
 February 9, 2017 by M
EDICAL RESEARCH CO
UNCL - UK SBS
http://jvi.asm.org/
D
ow
nloaded from
 
 o
n
 February 9, 2017 by M
EDICAL RESEARCH CO
UNCL - UK SBS
http://jvi.asm.org/
D
ow
nloaded from
 
 o
n
 February 9, 2017 by M
EDICAL RESEARCH CO
UNCL - UK SBS
http://jvi.asm.org/
D
ow
nloaded from
 
 o
n
 February 9, 2017 by M
EDICAL RESEARCH CO
UNCL - UK SBS
http://jvi.asm.org/
D
ow
nloaded from
 
 o
n
 February 9, 2017 by M
EDICAL RESEARCH CO
UNCL - UK SBS
http://jvi.asm.org/
D
ow
nloaded from
 
 o
n
 February 9, 2017 by M
EDICAL RESEARCH CO
UNCL - UK SBS
http://jvi.asm.org/
D
ow
nloaded from
 
TABLE 1 Oligonucleotide primers used in this study 
Target 
gene 
Primer 
name Sequence (5’ -3’) Region (nt) Size (bp) 
p11 pUNO-
HA-p11 
F: gtg gtcgac atg TAC CCA TAC GAT GTT CCA GAT TAC GCT GCT AAT TGC CGT CCG 
TTG CCT ATT GGG 
R: atc gctagc TCA TTG CGC CAC AAA CAC GTC 
13-39 165 
 
177-160 
 
p28 pUNO-
HA-p28 
F: ttt gtcgac atg TAC CCA TAC GAT GTT CCA GAT TAC GCT GGG GTG GTG GAT GAT 
TTC TTC CGC CCC 
R: atc gctagc TCA CTG CGG CGT GTA GAG GC 
178-204 762 
 
939-923 
 
p35 pUNO-
HA-p35 
F: tac gtcgac atg TAC CCA TAC GAT GTT CCA GAT TAC GCT GCA GGC AAT GAT CTC 
ATC ATA TTG GGG 
R: gac gctagc TCA CTC GCT GTT GTA CTT C 
940-966 1017 
 
1956-1941 
 
p32 pUNO-
HA-p32 
F: tac gtcgac atg TAC CCA TAC GAT GTT CCA GAT TAC GCT GCC GCT GAT GTC AAA 
CAT CTA TGG TTC   
R: ttt gctagc TCA CTC GCT AAG CGT GTT TTC 
1957-1983 855 
 
2811-2794 
 
VPg pUNO-
HA-VPg 
F: ac gtcgac atg TAC CCA TAC GAT GTT CCA GAT TAC GCT GCG AAA GGG AAA AAC 
AAA CGC GGA CGT 
R: gctagc TCA CTC ACT GTC ATA GGT GTC ACC TTT  
2812-2838 338 
 
3150-3133 
 
ProPol pUNO-
HA-
ProPol 
F: gtcgac atg TAC CCA TAC GAT GTT CCA GAT TAC GCT GGG CGT GGA TAC GTG GTA 
CCC ATG AC 
R: gctagc TCACTCCATCACGAACACTTCTGGCTCTTC  
3151-3177 1995 
 
5145-5128 
 
VP1 pUNO-
HA-VP1 
F: gtcgac atg TAC CCA TAC GAT GTT CCA GAT TAC GCT GAG GCG CCT GCC CCA 
ACC CGT TCG GTT 
R: gctagc TCATCGTGAGCTGTGAATGGACCTTCC  
5144-5169 1627 
 
6771-6753 
 
VP2 pUNO-
HA-VP2 
F: ctc gtcgac atg TAC CCA TAC GAT GTT CCA GAT TAC GCT AGT TGG ATT GCA GGA 
GCA ATG CAG GGC 
R: agg gctagc TCA TCA CAC TTT GCT GTG AGT G 
6774-6800 492 
 
7265-7247 
 
VPg  F: CAA ACG CGG ACG TGG TGC TCG 
R: TGA TGC GCC TGA CAG TGC GCG 
2826-2846 145 
 2970-2950  
*COX-1  F: CCG GAG GAA GTT CAT ACC TGA CCC 
R GCC AGG ACC CAT CTT GCC AGA 
253-275 108 
 360-340  
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**COX-2  F: CAC CCA TGG GTG TGA AAG GGA GG 
R: CCA AAG GAC AGG GCC ATG GGG 
181-203 201 
 381-361  
Small underlined letters: restriction enzyme sites (Forward primer: SalI; Reverse primer: NheI). 
Italic letters: polypeptide hemagglutinin sequences. 
Bold letters: start codon. 
*Derived from partial sequence of porcine COX-1; GenBank accession no. AF207823.1. 
**Derived from partial sequence of porcine COX-2; GenBank accession no. AF207824.1.  o
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